Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer Society. About 90 percent of these tumors carry mutations in a single gene, KRAS, that for decades was considered impossible to drug. Now, for the first time, two fundamentally different experimental strategies are producing early but real signs of progress against the disease at the same time: an oral pill designed to block the most common KRAS mutation in pancreatic cancer, and a personalized mRNA vaccine that trains each patient’s immune system to hunt down their specific tumor.
Neither approach has yet proven it extends survival. The data so far are limited to safety findings, immune readouts, and correlations with delayed cancer recurrence. But the biological signals coming out of these phase 1 trials are unlike anything researchers have seen before in a cancer that has resisted nearly every treatment thrown at it.
The pill: oral drugs that lock onto an “undruggable” protein
For years, KRAS earned a reputation as “undruggable” because the protein’s smooth, pocket-free surface gave small molecules almost nothing to grab. That changed in 2021 when the FDA approved sotorasib for lung cancer driven by a different KRAS variant, G12C, proving the protein could be targeted after all. Pancreatic cancer, however, is overwhelmingly driven by a different variant: KRAS G12D, found in roughly 40 percent of KRAS-mutant pancreatic tumors. Blocking G12D requires a different class of chemistry.
Two oral compounds are now in early human testing against KRAS G12D-mutant solid tumors, including pancreatic cancer. RMC-9805, developed by Revolution Medicines and classified as a KRAS G12D(ON) inhibitor, is in a dose-escalation study measuring safety and early signs of antitumor activity. A second drug, INCB161734 from Incyte, is running through its own dose-escalation and expansion trial in patients with the same mutation. Both trials list safety, pharmacokinetics, and preliminary antitumor activity as primary endpoints, per their ClinicalTrials.gov registrations.
As of late May 2026, neither trial has reported objective response rates or progression-free survival figures specific to pancreatic cancer patients in any public dataset. Both programs remain in dose-finding phases, meaning the immediate goal is establishing how much drug patients can safely tolerate, not yet measuring how effectively the drugs shrink tumors. Whether either inhibitor produces meaningful clinical responses in pancreatic cancer, as opposed to other G12D-driven tumors like certain colorectal or lung cancers, is a question the current data cannot answer.
The vaccine: teaching the immune system to recognize each patient’s tumor
The vaccine track has generated more published clinical evidence, and the results are striking for a disease where immunotherapy has historically failed.
Autogene cevumeran (also called BNT122), developed by BioNTech and Genentech, is an individualized mRNA neoantigen vaccine. After a patient’s tumor is surgically removed, researchers sequence its DNA, identify up to 20 unique mutations, and manufacture a custom mRNA payload that teaches the patient’s immune system to recognize those specific targets. In a study of 16 vaccinated patients with resected pancreatic cancer, published in Nature in 2023, the vaccine stimulated functional T-cell responses directed at each patient’s unique tumor mutations. Critically, those responses correlated with recurrence timing: patients who mounted stronger immune responses after vaccination went longer before their cancer came back.
A follow-up analysis, also published in Nature, confirmed that the vaccine primed long-lived CD8+ T cells, the immune system’s primary tumor-killing agents, and that the durability of these cells tracked with the clinical course of the disease. The persistence of these killer T cells months after vaccination suggests the immune memory generated by the mRNA approach is not short-lived. The same vaccine platform was also tested in a broader phase 1 trial across advanced solid tumors, with or without the checkpoint inhibitor atezolizumab, establishing safety and immune activation beyond the resected pancreatic cancer setting.
A separate vaccine program adds further evidence. ELI-002 2P, a lymph node-targeted vaccine specific to mutant KRAS developed by Elicio Therapeutics, was evaluated in the phase 1 AMPLIFY-201 trial. That study, published in Nature Medicine, enrolled pancreatic and colorectal cancer patients selected based on minimal residual disease detected through circulating tumor DNA (ctDNA), a blood-based marker of microscopic cancer that remains after surgery. The trial confirmed immune activation in this high-relapse-risk population. The ctDNA-guided enrollment strategy represents a deliberate effort to find patients most likely to benefit from immune intervention and to treat them during a narrow window when tumor burden is still low enough for the immune system to have a fighting chance.
The wide gap between immune signals and survival proof
Generating T cells that recognize a tumor is not the same as keeping a patient alive longer. That distinction matters enormously in oncology, and it is the central caveat hanging over all of these results.
The autogene cevumeran data are the most mature in this group because they link immune responses to a clinical outcome, delayed recurrence, in a peer-reviewed setting. That link is the strongest single piece of evidence supporting the idea that these approaches are gaining traction against pancreatic cancer. But the study was small (16 patients) and had no control arm, meaning the correlation between T-cell response and delayed recurrence, while encouraging, does not prove the vaccine caused the delay. Long-term overall survival data from this cohort have not been publicly reported.
For ELI-002 2P, the AMPLIFY-201 trial demonstrates that a KRAS-targeted vaccine can safely activate T cells in patients with minimal residual disease, but the study was not designed to show definitively that vaccination improves survival compared with standard care alone. Longer follow-up and controlled comparisons are necessary before the approach can be considered a proven treatment.
On the oral drug side, ClinicalTrials.gov entries for RMC-9805 and INCB161734 confirm that these programs exist and are actively enrolling, but registry records are administrative documents, not results. They are proof of activity, not proof of efficacy.
No published data exist on combining an oral KRAS inhibitor with an mRNA vaccine in the same patients. The idea that sequencing a targeted pill after adjuvant vaccination could produce additive benefit is scientifically plausible, particularly in patients with detectable minimal residual disease, but it is entirely untested. Researchers have not reported any combination results from listed registries or peer-reviewed papers. Whether overlapping toxicities, such as inflammation in normal tissues or immune-related side effects, would limit dosing in a combination regimen remains unknown.
What this means for patients exploring trial options in mid-2026
These strategies remain firmly experimental. Outside of clinical trials, surgery followed by chemotherapy (and sometimes radiation) remains the backbone of pancreatic cancer treatment, and that will not change until randomized trials comparing these new approaches against current standards produce mature results.
What has changed is the landscape of possibility. For the first time, researchers have biological proof that a personalized vaccine can wake up the immune system against a cancer that has long been considered immunologically cold, and that oral drugs can be engineered to hit a protein once deemed untouchable. Those are not cures. They are not yet even confirmed clinical benefits. But for a disease where progress has been measured in weeks of added life, the convergence of two distinct precision strategies showing biological traction at the same time represents a genuine shift in what scientists believe is achievable.
Patients interested in these approaches should discuss trial eligibility with their oncologists. Updated trial listings for KRAS-targeted therapies and mRNA neoantigen vaccines can be found at ClinicalTrials.gov.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
